Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032395 | 0.90 | NPY5R (0.51) | NPY5RKCNH2HSD11B1CYP2C19ALOX15 | |
| SCHEMBL3026753 | 0.86 | NPY5R (0.52) | NPY5RKCNH2HSD11B1 | |
| SCHEMBL3026756 | 0.86 | NPY5R (0.52) | NPY5RKCNH2HSD11B1 | |
| SCHEMBL3036527 | 0.86 | HSD11B1 (0.48) | NPY5RKCNH2HSD11B1CYP2C19ALOX15 | |
| SCHEMBL3026796 | 0.85 | HSD11B1 (0.49) | NPY5RHSD11B1ALDH1A1KMT2AKDM4E | |
| SCHEMBL13045628 | 0.85 | NPY5R (0.52) | NPY5RKCNH2HSD11B1CYP2C19ALDH1A1 | |
| SCHEMBL13045562 | 0.85 | NPY5R (0.52) | NPY5RKCNH2HSD11B1CYP2C19ALDH1A1 | |
| SCHEMBL3027552 | 0.85 | NPY5R (0.52) | NPY5RKCNH2HSD11B1CYP2C19ALDH1A1 | |
| SCHEMBL3036715 | 0.85 | HSD11B1 (0.48) | NPY5RKCNH2HSD11B1ALDH1A1KMT2A | |
| SCHEMBL13045573 | 0.84 | HTT (0.48) | NPY5RKCNH2HSD11B1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008129007-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | NPY5R 1/4885KCNH2 3498/4885HSD11B1 1243/4885 |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | NPY5R, NPY4R, NPY1R | NPY5R 1/4885KCNH2 315/4885HSD11B1 1359/4885 |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | NPY5R, NPY1R, NPY4R | NPY5R 1/4885KCNH2 1865/4885HSD11B1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.